SBP GROUP

1177
5.5100.90% ( -0.050 )
Delay Closed: Nov 16, 16:08:11

Overview

SBP GROUP (1177)

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of Ch...

Open
5.530
High
5.560
Low
5.410
Prev. Close
5.560
Volume
67.13M
Turnover
368.80M
Avg Price
5.494
Bid/Ask Ratio
-93.51%
Amplitude
2.70%
52wk High
7.360
Volume Ratio
0.59
Turnover Ratio
0.36%
52wk Low
4.120
HK Mkt Cap
102.94B
Market CapHKD
102.94B
P/ETTM
37.42
P/EDynamic
13.02
P/EStatic
--
EPSTTM
0.147
EPSDynamic
0.423
EPSStatic
--
BVPS
2.01
P/B
2.75
HK Shares
18.68B
Dividend YieldTTM
2.18%
DividendTTM
0.120
Shares
18.68B
Min lot size
1,000
Currency
HKD

SBP GROUP Analyst Rating

View more

Forecast & Rating

Nov 6, 2026
Price forecast
HK$8.4853.85%
Forecast & RatingStrong buy
23analysts
  • Strong buy69.57%
  • Buy21.74%
  • Hold8.70%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Sino Biopharmaceutical edged down today, closing at HKD 5.51, declining roughly 0.9%, as profit-taking emerged following recent strength. The company has secured a significant milestone through a collaboration with Boehringer Ingelheim valued at up to USD 7.4 billion for oncology drug development and commercialization, backed by analyst support including CICC's maintained Buy rating and UOB Kay Hian's raised target price to HKD 7.5. Latest Q2 earnings show operating revenue of HKD 11.23 billion, up 16.62% year-over-year, with operating profit surging 104.47% year-over-year and net profit reaching HKD 1.98 billion, up 6.84% year-over-year, reflecting a net margin of 17.66% and ROE of 21.09%. However, the current price remains 26% below the 52-week high of HKD 7.48, down 13.36% year-to-date, with a P/E multiple of 37.4x reflecting elevated market expectations for future growth.

  2. Nov, 13

    The stock pulled back slightly by 0.18% to close at HK$5.56, but intraday volatility reached 3.4% as the morning session peaked at HK$5.65 before afternoon profit-taking. Recent catalysts—a US$7 billion oncology partnership with Boehringer Ingelheim and positive Phase II data for hepatitis B drug TQ-A3334 (20.8% antigen clearance in high-dose patients)—drove a 15% weekly rally that prompted UOB Kay Hian to raise target price to HK$7.5. Today's pullback largely reflects profit-taking after these near-term catalysts were already priced in. On earnings, Q2 revenue of HK$11.23 billion grew 16.6% year-over-year, with operating profit surging 105.5% to HK$3.82 billion—a significant operational improvement alongside a stable net margin of 17.7% and ROE exceeding 21%. The stock trades 25.7% below its 52-week high of HK$7.48 and sits above both the 20-day and 60-day moving averages; it has declined 12.6% year-to-date from an opening price of HK$6.36 but recovered 32.7% from its 52-week low. However, a forward P/E of 37.8x remains elevated for the pharma sector, requiring sustained product commercialization to justify the growth premium.

  3. Nov, 12

    Hong Kong shares closed marginally up 0.63%, but faced profit-taking pressure in afternoon trading following the recent announcement of Boehringer Ingelheim's $7 billion oncology partnership, retreating from the intraday high of HKD 5.615 at 13:02 to close at HKD 5.57. Recent catalysts remain positive: TQB2102 achieved 71% reduction in disease progression or death in breast cancer Phase III, and two hepatitis B drugs won China breakthrough designation; UOB Kay Hian raised target price to HKD 7.5. Q2 fundamentals showed operating profit surging 104.47% year-over-year to HKD 38.2 billion, revenue growing 16.62% to HKD 11.23 billion, and EPS advancing 6.97% to HKD 0.1103. Year-to-date the stock has declined 12.42% and sits 25.53% below the 52-week high of HKD 7.48. The elevated PE of 37.83, however, requires sustained earnings momentum to justify current valuation.

  4. Nov, 11

    China Biopharmaceutical gapped lower at 5.50 following the announcement of a $7-7.4 billion oncology collaboration with Boehringer Ingelheim, with morning weakness driving the stock to 5.465 and a session low of 5.43 as profit-takers capitalized on the catalyst. The afternoon saw steady recovery to close at 5.535, reflecting confidence in the partnership's strategic value. Recent quarters delivered solid growth: Q1 and Q2 revenues rose 17.34% and 16.62% respectively, with net profit gains of 7.5% and 6.84%, while net margins held steady at 17.66%. UOB Kay Hian raised its target to HKD7.5, projecting the $7B partnership to accelerate growth in the coming year. Pipeline highlights include TQ-A3334 clearing HBsAg in 20.8% of patients in Phase II hepatitis B studies, and TQB2102 reducing progression or death risk by 71% in Phase III breast cancer trials. At PE 37.59, valuations remain stretched, and with the stock down 12.97% year-to-date and 26% below its 52-week high of 7.48, sustained clinical progress is needed to justify current levels.

  5. Nov, 10

    Sino Biopharmaceutical rose 1.55% to HKD 5.555 today, primarily driven by profit-taking after a significant rally over the past week. The stock surged over 15% following the company's landmark USD 7.4 billion oncology partnership with Boehringer Ingelheim, announced on November 5th. Today also saw new clinical data for TQ-A3334 (hepatitis B program), showing a 20.8% HBsAg clearance rate in high-dose patients during Phase II trials. Analyst support remains, with UOB Kay Hian maintaining an HKD 7.5 target price, implying 35% upside. Fundamentals stayed solid: Q2 operating profit surged 104.47% year-over-year while revenue grew 16.62%. On valuation metrics, the stock trades 25.74% below its 52-week high of HKD 7.48 and is down 12.66% year-to-date, though it remains above both the 20-day and 60-day moving averages. The P/E ratio of 37.73x, however, reflects elevated valuation expectations tied to near-term catalysts.

News

Bullish vs. Bearish — Last 3 Months

9.0k followers · 0 opinions
▲Bullish50%
50%Bearish▼